Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Friday. The brokerage issued a sell rating on the stock.

Syros Pharmaceuticals Stock Down 41.4 %

Shares of NASDAQ SYRS opened at $0.06 on Friday. Syros Pharmaceuticals has a 52-week low of $0.06 and a 52-week high of $6.93. The business’s 50 day moving average is $0.16 and its two-hundred day moving average is $0.85. The firm has a market cap of $1.65 million, a price-to-earnings ratio of -0.02 and a beta of 1.31.

Hedge Funds Weigh In On Syros Pharmaceuticals

Several institutional investors have recently modified their holdings of SYRS. Exome Asset Management LLC boosted its holdings in Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after purchasing an additional 139,400 shares during the period. Two Sigma Securities LLC purchased a new stake in Syros Pharmaceuticals during the 4th quarter worth about $25,000. Finally, GSA Capital Partners LLP acquired a new stake in Syros Pharmaceuticals in the 3rd quarter valued at about $34,000. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.